InvestorsHub Logo
Followers 2
Posts 105
Boards Moderated 0
Alias Born 10/18/2019

Re: None

Friday, 11/08/2019 6:58:19 AM

Friday, November 08, 2019 6:58:19 AM

Post# of 17485
Yesterday's NR is very important from an efficacy stand point. it proved that VCS does NOT have any impact on the healing properties of MMF, unlike other CNIs like cyclosporine who "has resulted in a 30 – 50% reduction in MPA exposure when used in combination". The fact that VCS does not reduce the efficacy of MMF is resulting in higher CR rates and response durability as we saw in AURA.
The recent results in this DDI study is an indication that CR rates similar to AURA will become a normality in AURORA or any other future trial. Huge News yesterday
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News